KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Change in Cash (2018 - 2025)

Historic Change in Cash for Moderna (MRNA) over the last 8 years, with Q3 2025 value amounting to -$147.0 million.

  • Moderna's Change in Cash rose 8235.29% to -$147.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$513.0 million, marking a year-over-year increase of 6071.98%. This contributed to the annual value of -$999.0 million for FY2024, which is 24567.47% down from last year.
  • As of Q3 2025, Moderna's Change in Cash stood at -$147.0 million, which was up 8235.29% from -$345.0 million recorded in Q2 2025.
  • Moderna's Change in Cash's 5-year high stood at $2.8 billion during Q1 2021, with a 5-year trough of -$2.2 billion in Q2 2022.
  • For the 5-year period, Moderna's Change in Cash averaged around -$79.1 million, with its median value being -$25.0 million (2023).
  • In the last 5 years, Moderna's Change in Cash skyrocketed by 170576.92% in 2021 and then tumbled by 145093.17% in 2022.
  • Moderna's Change in Cash (Quarter) stood at $1.3 billion in 2021, then crashed by 86.45% to $176.0 million in 2022, then plummeted by 114.2% to -$25.0 million in 2023, then skyrocketed by 1228.0% to $282.0 million in 2024, then plummeted by 152.13% to -$147.0 million in 2025.
  • Its Change in Cash was -$147.0 million in Q3 2025, compared to -$345.0 million in Q2 2025 and -$303.0 million in Q1 2025.